The Cancer Proteomics Core pushes the limits of proteomics and metabolomics technologies and specializes in cancer projects utilizing blood, urine, cerebrospinal fluid, saliva, cyst fluids, interstitial fluids, cell and tissue extracts to: gain insight into cancer processes;discover new biomarkers for early detection, diagnosis, prognosis and outcome prediction;study population effects;manage clinical trials;evaluate drug efficacy and toxicity;stratify patients;identify tumor antigens;and accelerate drug development. A unique aspect of the CPC has been its expertise in basic, translational and clinical cancer research, as well as in proteomics, metabolomics, systems biology, and bioinformatics. Unlike other proteomics facilities, the staff is able to provide expertise in all aspects of cancer research, as well as study design and data analysis and understands the complexities and challenges of proteomics projects. The Core was first approved as an Established Shared Resource in the CCSG renewal application. It has been directed by Towia Libermann, PhD, since its founding in 2004. This facility has grown considerably during the project period, with a steady increase in usage. Director: Towia Libermann, PhD(BIDMC) Category: 1.36 (Proteomics) Management: Joint (Cancer Center and Institutional)

Public Health Relevance

The Core provides investigators involved in clinical and translational studies with access to comprehensive high sensitivity, high resolution and high throughput proteomics and metabolomics services. There is particular emphasis on clinical sample analysis and in-depth scientific consultation in proteomics, metabolomics and data analysis. Basic researchers who are exploring signaling pathways and other aspects of cancer biology are also able to receive access to sophisticated proteomic and metabolomic services and expert consultation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8228323
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$276,783
Indirect Cost
$69,350
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574
Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641
Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351

Showing the most recent 10 out of 411 publications